<DOC>
	<DOCNO>NCT00088465</DOCNO>
	<brief_summary>This long-term , open-label clinical study design enable longer-term treatment patient complete clinical study intramuscular olanzapine depot . Key objectives study : - Determine well intramuscular ( IM ) olanzapine depot work long-term treatment , - Evaluate safety tolerability IM olanzapine depot long-term treatment , - Determine blood level IM olanzapine depot patient long-term treatment</brief_summary>
	<brief_title>Open-Label Study Intramuscular Olanzapine Depot Patients With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients must schizophrenia Female patient childbearing potential must use medically accept mean contraception Patients must complete ( within 10 day ) another IM olanzapine depot study permit study 's protocol . Patients must participate clinical trial another investigational drug , include olanzapine , within 1 month ( 30 day ) prior study entry Female patient must pregnant breastfeed Patients must experience acute , serious unstable medical condition schizophrenia schizoaffective disorder Patients must substance ( except nicotine caffeine ) dependence within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>